Pricing Log in Create free account
Saturday 17 October 2026 Export MRK’s income statement to Excel — free account

Merck & Co., Inc.

MRK Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.

145.95 0.76 +0.52%
Market cap
$358.2B
P/E
117×
Fwd P/E
53.9×
Dividend yield
2.33%
F-score
4/9
Altman Z
3.77
Beneish M
−2.27
Dividend safety
74/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Merck & Co., Inc. (MRK) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Merck & Co., Inc. (MRK) trades at a EV/EBITDA of 29.5×. Over the past ten years it has ranged from 8.4× (May 2025) to 52.9× (March 2024); the current reading is higher than 92% of that period. That is above the Drug Manufacturers General industry median of 13.8× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 10.6× (4.11%)
FY2024 11.0× (76.01%)
FY2023 46.0× 243.62%
FY2022 13.4× 1.45%
FY2021 13.2× (44.52%)
FY2020 23.8× 13.73%
FY2019 20.9× 37.03%
FY2018 15.3× 9.85%
FY2017 13.9× (9.70%)
FY2016 15.4× 40.55%

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 26.4× 49.84%
Mar 2026 17.6× 66.44%
Dec 2025 10.6× 23.35%
Sep 2025 8.6× (6.53%)
42 more quarters

Against its own ten years

Low 8.4× High 52.9×
Ten-year median 15.1×
Current reading's percentile 92

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
PFE Pfizer Inc. compare 10.8×
AZN AstraZeneca PLC compare 13.8×
NVS Novartis AG compare 14.5×
AMGN Amgen Inc. compare 16.8×
JNJ Johnson & Johnson compare 18.1×
ABBV AbbVie Inc. compare 22.2×
MRK Merck & Co., Inc. 29.5×
GILD Gilead Sciences, Inc. compare 829×
Drug Manufacturers General industry median 13.8×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on MRK